WO2001030234A9 - Method and apparatus for determining cardiac output - Google Patents
Method and apparatus for determining cardiac outputInfo
- Publication number
- WO2001030234A9 WO2001030234A9 PCT/US2000/041281 US0041281W WO0130234A9 WO 2001030234 A9 WO2001030234 A9 WO 2001030234A9 US 0041281 W US0041281 W US 0041281W WO 0130234 A9 WO0130234 A9 WO 0130234A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- oxygen concentration
- arterial oxygen
- arterial
- determining
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/083—Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
- A61B5/0833—Measuring rate of oxygen consumption
Definitions
- the present invention pertains to a method and apparatus for determining the cardiac output of a patient, and, more particularly, to a method of determining cardiac output by analyzing the effect that an induced change in the patient's arterial oxygen concentration has on their oxygen uptake and fractional arterial oxygen concentration, and to an apparatus for use in implementing such a method.
- CO which is the total volumetric flow of blood through the heart, and, thus, through the body at any given time.
- Thermodilution involves injecting cold saline directly into the right atrium of the heart and measuring the temperature change downstream in the pulmonary artery using a temperature sensor placed in this artery. Cardiac output is determined based on this temperature change.
- Dye dilution is similar to thermodiluation except that a dye, rather than cold saline, is injected into the art. The amount of dye collected downstream is measured to determine the patient's cardiac output.
- the direct Fick method either the content of oxygen (O ) or the content of carbon dioxide (CO 2 ) in both the arterial blood and mixed venous blood are measured.
- the direct Fick method requires obtaining a mixed venous blood sample, which is only available in the pulmonary artery. See Fig. 1.
- thermodilution, dye dilution, and the direct Fick method for determining cardiac output all require insertion of a catheter into the patient at, near, or through the heart. More specifically, in implementing these cardiac output measurements, a catheter is usually floated through the chambers of the heart in order to insert the saline or dye or to obtain the necessary blood sample at the correct location. For this reason, either of the above cardiac output measurement techniques is very invasive. Indeed, it is known that an arrhythmia may result from the placement of the catheter in or through the heart. Therefore, these cardiac output measurement techniques are typically only performed in the most critical of situations, where the need to know the patient's cardiac output outweighs the risk to the patient in taking this measurement.
- the partial CO 2 rebreathing technique for measuring cardiac output is a noninvasive approach believed to have been developed by Novametrix Medical Systems, Inc. of Wallingford, Connecticut (Novametrix). This method is implemented using a device referred to as a NICOTM sensor, which is distributed by Novametrix.
- the NICO sensor measures the flow of gas to and from the patient and the CO 2 content in the patient's exhaled gas.
- the partial CO 2 rebreathing cardiac output measurement technique is based on the CO 2 Fick equation in conjunction with what is called partial CO 2 rebreathing.
- cardiac output is measured by comparing the patient's CO 2 excretion to the arterial CO 2 content during normal breathing and during rebreathing, in which the patient rebreathes expired gases for a period of time.
- This partial CO 2 rebreathing technique has several disadvantages. Namely, the patient is preferably intubated or breathing through a trachea tube when taking the flow and CO 2 measurements to capture the total volume of CO 2 . In addition, the patient must be heavily sedated or unconscious so that he or she is not breathing spontaneously. If the patient is breathing spontaneously, the increased CO 2 level in the blood during the rebreathing phase would automatically trigger the patient's respiratory system to speed up or deepen the breaths to remove the excess CO . It is well known that for most patient's the level of CO 2 , not the level of O 2 , is the mechanism for triggering ventilation. Such rapid or deep breathing prevents an accurate determination of cardiac output under this technique.
- end tidal CO 2 may introduce errors in determining cardiac output, because the are situations where the end tidal CO 2 may not correlate with the arterial CO 2 content.
- the partial CO 2 rebreathing cardiac output measurement technique is also disadvantageous because it does not adequately account for shunt blood flow, which is blood that is not oxygenated during the respiratory cycle. This flow cannot be directly measured, but must be estimated when using this conventional cardiac output measurement technique.
- a cardiac output measurement method that includes quantitatively measuring a patient's airflow, a first parameter indicative of a percent oxygen inhaled and exhaled by the patient, and a second parameter indicative of the patient's fractional arterial oxygen concentration.
- the present method also includes inducing a change in the patient's arterial oxygen concentration and repeating these measurements to monitor the effects resulting from inducing the change in the patient's arterial oxygen concentration.
- the patient's cardiac output is determined based on the data collected.
- This object is achieved by providing an apparatus that includes a patient flow measuring system capable of quantitatively measuring a patient's airflow, i.e., the flow of gas to and from a patient, an oxygen analyzing system adapted to measure a first parameter indicative of a percent oxygen inhaled and exhaled by such a patient, and means for measuring a second parameter indicative of the patient's fractional arterial oxygen concentration, such as a pulse oximeter.
- a processor determines the cardiac output based on the measured patient airflow, the first parameter, and the second parameter.
- an output device outputs the result indicative of the patient's cardiac output.
- Fig. 1 is a schematic diagram of mammalian cardio-pulmonary system
- Fig. 2 is an oxygen-hemoglobin dissociation curve for a human
- Fig. 3 is a graph illustrating the change in oxygen uptake that takes place during an induced change in arterial oxygen concentration according to the cardiac output measurement method of the present invention
- Fig. 4 is a graph illustrating the change in arterial oxygen saturation resulting from the induced change in arterial oxygen concentration
- Figs. 5 and 6 are graphs illustrating the change in oxygen uptake and arterial oxygen concentration, respectively, resulting from the induced change in arterial oxygen concentration including the potential effects of recirculation;
- Figs. 7 and 8 are graphs illustrating the change in oxygen uptake and arterial oxygen concentration, respectively, resulting from the induced change in arterial oxygen concentration illustrating an alternative embodiment for determining cardiac output based on these changes;
- Figs. 9 and 10 are graphs illustrating the change in oxygen uptake and arterial oxygen concentration, respectively, resulting from the induced change in arterial oxygen concentration illustrating yet another alternative embodiment for determining cardiac output based on these changes;
- Fig. 11 is a schematic diagram of a device for implementing the cardiac output measurement method of the present invention.
- Fig. 12 is a schematic diagram of the device of Fig. 11 shown in use on a patient.
- Fig. 1 schematically illustrates a patient's cardio-pulmonary system, which is useful in understanding the cardiac output measurement system of the present invention.
- the cardiac output measurement technique of the present invention measures the output, i.e., rate of flow of blood, from the left side of the heart.
- the cardiac output measurement method of the present invention uses the transfer of oxygen from the lungs to the arteries in order to determine cardiac output.
- the presently preferred method of determining the cardiac output includes the following steps, each of which is discussed in detail below: (1) quantitatively measuring (a) the patient's airflow, (b) a parameter indicative of the percent oxygen inhaled and exhaled by the patient, and (c) a parameter indicative of the patient's fractional arterial oxygen concentration (XaO 2 );
- the patient's cardiac output is determined based on the change in oxygen uptake versus the change in fractional arterial oxygen concentration resulting from the induced change in the arterial oxygen concentration.
- the patient's arterial oxygen concentration is what is being manipulated in order to induce a change in the patient's oxygen uptake and fractional arterial oxygen concentration.
- this method can be performed on a spontaneously breathing patient, as well as a patient who is not spontaneously breathing. Unlike changing the patient's CO 2 concentration, changing the patient's arterial O 2 concentration will not cause the patient to automatically attempt to alter their breathing pattern to move the O 2 concentration back to normal. Because this cardiac output measurement technique involves inducing a change in the patient's arterial oxygen concentration, it is referred to as an oxygen concentration modification cardiac output measurement method.
- the patient's fractional arterial oxygen concentration is measured non-invasively using a conventional pulse oximeter.
- the oxygen concentration modification cardiac output measurement method of the present invention can be performed non-invasively on a spontaneously breathing patient.
- the patient's quantitative airflow and a parameter indicative of the percent oxygen inhaled and exhaled by the patient are measured to determine the patient's oxygen uptake.
- Oxygen uptake is the amount of oxygen absorbed into the blood in the lungs. It is typically expressed in liters as NO 2 or in liters per minute (1pm)
- equation (1) can be rewritten as follows:
- ⁇ XaO 2 Oxygen uptake which is measured during a breathing cycle, is determined by measuring the volumetric airflow Q pa tient to and from the patient, the %O 2 inhaled, and the %O 2 exhaled during that breathing cycle. Volumetric airflow is measured using a flow meter, such as a conventional pneumotach, that is capable of quantitatively measuring the flow of gas to and from the patient's airway.
- a flow meter such as a conventional pneumotach
- the %O 2 inhaled and %O 2 exhaled is measured using a conventional oxygen analyzer.
- An example of a combination flow sensing element and O 2 concentration analyzer window suitable for use in the present invention is taught in provisional U.S. Patent Application No. 60/170,918, the contents of which are incorporated herein by reference.
- FIO 2 inspired oxygen
- VO 2 exhaled j(Q patient [%O 2 /100])dt , atid (5)
- NO 2 NO 2 inhaled - VO 2 exhaled, (6)
- ti the start of inhalation
- t 2 the end of inhalation or start of exhalation
- t 3 the end of exhalation.
- Oxygen uptake in liters per minute is then determined as:
- NO 2 NO 2 * f breath , (7) were f breath is the frequency of breaths, i.e., breaths per minute.
- XaO 2 fractional arterial oxygen concentration
- One embodiment of the present invention contemplates measuring at least one the following blood gas constituents, SaO 2 , PaO 2 , and CaO as the parameter indicative of the patient's fractional arterial oxygen concentration XaO 2 .
- These parameters are measured from an arterial blood sample or using a continuously indwelling catheter. It is preferable for one or more of these constituents to be measured continuously, for example, using an indwelling catheter so that the effects of the induced change in arterial oxygen concentration on the oxygen uptake and fractional arterial oxygen concentration can be monitored on a substantially continuous basis. This is especially important because of the relatively short duration of the effects of the induced change in arterial oxygen concentration resulting from the oxygen concentration modification step.
- the present invention also contemplates measuring the pulse oximetry oxygen saturation level (SpO 2 ) of the patient as the parameter indicative of the fractional arterial oxygen concentration XaO 2 .
- This measurement is advantageous in that the SpO 2 can be measured non-invasively using a conventional pulse oximeter. It can also be taken on a generally continuous basis to closely monitor the effects of the induced oxygen concentration modification on the patient's actual fractional arterial oxygen concentration.
- the SpO 2 level can be taken from almost any location on the patient, such as the finger or ear, in a preferred embodiment, the SpO 2 is measured across the nasal septum. This location is especially desirable because it represents a relatively direct flow from the carotid artery, as shown in Fig. 1.
- SaO 2 is the measured parameter, a conversion is needed, so that the measured SaO 2 can be used as the fractional arterial oxygen concentration XaO 2 .
- XaO 2 fractional arterial oxygen concentration
- Vol % O 2 (Hb concentration) (O 2 saturation (SaO 2 ) )(O 2 carrying capacity of Hb), (8) where, for a normal adult, the O 2 carrying capacity of hemoglobin (Hb) is approximately 1.34 mlO 2 /gmHb, and the Hb concentration is approximately 15 gmHb/lOOmlblood. Thus, for a normal adult:
- Equation (9) can be simplified as:
- Hb concentration 15 gmHb
- O 2 carrying capacity of Hb (1.34 mlO 2 )
- k value a more exact relationship between SaO and XaO 2
- the present invention contemplates that the values for Hb concentration and/or O 2 carrying capacity of Hb can be directly input by the user, automatically input from measurements taken by a co-oximeter or other equivalent device via a communication link with such a device, manually or automatically selected from a range of values based on information about the patient, or a default value can be used.
- Fig. 2 This nonlinear relationship is graphically depicted in Fig. 2, which is referred to as an oxygen-hemoglobin dissociation curve 10.
- PaO 2 is the measured parameter, it must first be converted to an SaO 2 using the dissociation curve, which can be accomplished using any conventional technique. Thereafter, the conversion factor k for SaO 2 must be used to arrive at the patient's fractional arterial oxygen concentration XaO 2 as discussed above.
- a patient's SaO 2 , PaO 2 , or CaO 2 can only be measured by sampling the patient's arterial blood or using a continuously indwelling catheter, either of which is a relatively invasive procedure.
- SpO 2 on the other hand, which is an estimation of SaO 2 , is measured non-invasively.
- the present technique for determining a patient's cardiac output involves inducing a change the patient's arterial oxygen concentration. This can be done in a variety of ways, several of which are discussed below, so long as there is a measurable difference between the patient's baseline arterial oxygen concentration and the patient's arterial oxygen concentration following the induced change therein. Because the goal of this process is to force a change in the patient's arterial oxygen concentration, this step in the cardiac output measurement process of the present invention is referred to herein as the "oxygen concentration modification step.”
- the arterial oxygen concentration can either be increased or decreased depending on the condition of the patient.
- a generally healthy patient has an oxygen saturation level of approximately 98 %.
- the present invention contemplates reducing the patient's oxygen saturation as one technique for inducing a change in the patient's arterial oxygen concentration, especially in those patients with a relatively high baseline SaO 2 .
- Reducing the patient's oxygen saturation can be accomplished by reducing the fraction of inspired oxygen (FIO 2 ) in the patient's inhaled gas.
- the patient breathes nitrogen for one or more breaths, thereby reducing their arterial oxygen concentration.
- This technique is particularly suited for patients with a relatively high baseline oxygen concentration.
- changing the patient's arterial oxygen concentration can also be accomplished by increasing the fraction of inspired oxygen in the inhaled gas. This can be accomplished, for example, by adding supplemental oxygen to the patient's inhaled gas, and, therefore, is particularly suited for patients with a relatively low baseline oxygen concentration.
- the present invention also contemplates changing the patient's arterial oxygen concentration by having the patient rebreathe expired gas. However, because this will raise the patient's CO 2 level, this technique is best used on non-spontaneously breathing patients, where increased levels of CO 2 will not cause unusual breathing patterns. For a non- spontaneously breathing patient, the present invention also contemplates changing the arterial oxygen concentration by momentarily pausing the ventilator used to provide the patient's breathing.
- Rebreathing expired gas can be used to change the patient's arterial oxygen concentration in a spontaneously breathing patient if steps are taken to minimize the increase in the patient's CO 2 level.
- the carbon dioxide CO 2 is preferably is removed from the rebreathed gas so that the patient does not dramatically alter their breathing pattern due to rebreathing of exhaled carbon dioxide.
- An exemplary embodiment of the present invention contemplates using a conventional CO "scrubbing" technique for removing the CO 2 from the gas rebreathed by the patient. This is accomplished, for example, by placing a CO 2 scrubber in the rebreathing circuit or by passing the patient's exhaled gas through a CO 2 scrubber before it is returned to the patient. In either case, the rebreathed gas will have a lower oxygen concentration, thereby accomplishing the goal of changing the patient's arterial oxygen concentration without having the patient breathing CO 2 , which will likely trigger a relatively rapid increase in the patient's breath rate.
- the present invention contemplates several techniques for calculating cardiac output based on the changes in oxygen uptake and the change in fractional arterial oxygen concentration resulting from the induced change in arterial oxygen concentration. Each of these techniques is discussed in turn below.
- N Q volume and t is time. For a given period of time, t a to t b , the rate of flow of fluid during that period is determined as follows:
- Equation (16) cannot be used to determine a patient's cardiac output because it does not take into consideration the fact that in the pulmonary system, the venus blood contains a predetermined level of oxygen before it is oxygenated in the lungs. In addition, this equation does not take into consideration blood that is shunted across the lungs and does not get oxygenated during a breathing cycle.
- the present invention takes these items into consideration and accounts for their effect by, in essence, determining the baseline oxygen concentration and oxygen uptake for the patient, then executing the oxygen concentration modification step, in which the patient's fractional arterial oxygen concentration is changed from the baseline value.
- the present invention determines cardiac output by monitoring the arterial oxygen concentration and oxygen uptake during this oxygen concentration modification step and by comparing the changes in the arterial oxygen concentration and oxygen uptake to the baseline levels.
- Fig. 3 is a graph that illustrates the change in a patient's oxygen uptake, NO 2 , that takes place during the oxygen concentration modification step, in which a change in the arterial oxygen concentration, XaO 2 , is induced using any of the above-described techniques. More specifically, Fig. 3 illustrates the change in oxygen uptake that takes place by having the patient take one breath, i.e., from time t to t , that is relatively devoid of oxygen. It should be noted that the change in oxygen uptake is illustrated in a step fashion because oxygen uptake is measured and calculated on a breath-by-breath basis. As shown in Fig. 3, it takes several breaths for the patient's oxygen uptake to stabilize back to its baseline level. Area A in Fig. 3 represents the change in the oxygen uptake ⁇ VO 2 of the patient that occurs as a result of oxygen concentration modification step.
- Fig. 4 illustrates the change in arterial oxygen saturation SaO 2 resulting from the induced change in arterial oxygen concentration, which, in this embodiment, involves having the patient take one breath that is devoid of oxygen.
- Area B in Fig. 4 represents the change in arterial oxygen concentration ⁇ XaO 2 that occurs as a result of oxygen concentration modification step.
- V U 2 V KJ2 baseline " » *-'2 after oxygen concentration modification ( 1 o)
- ⁇ XaO 2 XaO baseline " XaO after oxygen concentration modification ( 9)
- the present invention contemplates summing the oxygen uptake that occurs for each breath over the entire time, t a to t b , that the oxygen uptake is shifted from baseline, which, in effect, amounts to determining the area A under the curve, which is why this technique is referred to in the section heading as "Calculating Cardiac Output Based on the Area Under the Curves.”
- the patient's arterial oxygen concentration will also shift from its baseline level for a period of time t c to tj.
- the present invention contemplates finding the average arterial oxygen concentration resulting from the oxygen concentration modification step. It should be noted that the change in arterial oxygen concentration does not coincide with the start of the oxygen concentration modification step, i.e., t c ⁇ t a , because it takes some time for the change in inspired oxygen level to affect the patient's arterial oxygen concentration.
- equation (19) for the present invention is rewritten as: ⁇ VO 2
- Equation (20) can be written in greater detail as:
- Figs. 5 and 6 are similar to Figs. 3 and 4, respectively, except that Figs. 5 and 6 take into consideration a scenario in which the patient's blood begins to recirculate at time x during the oxygen concentration modification step. It can be appreciated from Fig. 5, that the patient's oxygen uptake may increase above baseline and then eventually return to its baseline level at time t b ⁇ . It this situation, the only area of interest is the area under the baseline, i.e., area Ai. That is, the effects of recirculatation, and, hence, area A 2 should be ignored in solving equation (21). For this reason, the present invention contemplates extrapolating to determine the baseline crossing point, which corresponds to point t b in equation (21). Thus, the change in oxygen uptake resulting from the oxygen concentration modification step, in this situation, will take into consideration the sum of areas A t and A 2 for purpose of solving equation (21), ignoring area A 3 above the baseline.
- Fig. 6 illustrates that a second drop in the patient's arterial oxygen saturation will occur at time x due to the recirculation of the relatively oxygen poor blood. If this second drop, which is represented by area B 2 , is minimal, it can be ignored for purposes of determining the time period t c to t d . Thus, the time period t c to t d2 associated with areas Bi and B 2 are used to solve equation (21).
- Figs. 7 and 8 like Figs. 3 and 4, illustrate the changes in the patient's oxygen uptake and arterial oxygen saturation, respectively, resulting from the oxygen concentration modification step. From Fig. 7, it can be appreciated that the change in oxygen uptake that takes place during the first breath of the oxygen concentration modification step can be defined in terms of its slope as:
- Equation (23) defines the slope of dashed line C in Fig. 7.
- FIGs. 9 and 10 illustrate the changes in the patient's oxygen uptake and arterial oxygen saturation, respectively, resulting from the oxygen concentration modification step. From Fig. 9, it can be appreciated that there is a relatively large initial drop in oxygen uptake at the start of the oxygen concentration modification step, i.e., from time ti to t . The magnitude of this drop can be determined from the output of the flow sensor and the oxygen analyzer using any conventional technique. From Fig. 10, it can be appreciated that there is corresponding drop in arterial oxygen saturation. Although, as noted above, this drop in arterial oxygen concentration is delayed in time from the initial drop in oxygen uptake.
- the value of the fractional arterial oxygen concentration at t m can be determined using any conventional technique.
- the oxygen concentration modification step also contemplates increasing the patient's arterial oxygen in some situations. In which case, the change in oxygen uptake will be in the positive direction, opposite that shown in Figs. 3, 5, 7, and 9. Similarly, the change in the fractional arterial oxygen concentration will also be in the positive direction, opposite that shown in Figs. 4, 6, 8, and 10.
- the techniques for determining cardiac output discussed herein are equally applicable where the oxygen concentration modification step in performed by increasing the patient's arterial oxygen.
- equation (28) represents a direct calculation for cardiac output because the units represented by the numerator are, for example, liters/second or liters/minute, and the denominator is unitless.
- equation (29) also represents a direct calculation for cardiac output because the unit represented by the numerator are, for example, liters/second or liters/minute, and the denominator is unitless.
- the change in magnitude of the oxygen uptake and fractional arterial oxygen concentration are monitored during the oxygen modification step, which is why this technique is referred to in the preceding section heading as the "Magnitude of the Curve" technique.
- Vache Qbiood - i!£ ⁇ L - (31)
- equation (30) can be substituted into equation (31) to determine the cardiac output.
- One embodiment of the present invention contemplates determining the baseline oxygen uptake and baseline arterial oxygen concentration before performing the oxygen concentration modification step so that the changes in oxygen uptake and baseline arterial oxygen concentration resulting from the oxygen concentration modification step can be compared to this baseline. It is to be understood, however, that in an alternative embodiment of the present invention, the baseline oxygen uptake and baseline arterial oxygen concentration are established after the effects of the oxygen concentration modification step; namely, after the patient's cardio-pulmonary system has returned to a steady state following the oxygen concentration modification step.
- Figs. 11 and 12 schematically illustrate an exemplary embodiment of a cardiac output measurement device 30 used to implement the above-described cardiac output measurement method.
- Cardiac output measurement device 30 includes a patient flow measurement system 32 for quantitatively measuring the flow of gas to and from the patient and an oxygen analyzer 34 that measures the patient's fraction of inspired oxygen (FIO 2 ).
- Patient flow measurement system 32 includes a flow sensor 33, also referred to as a flow element, that creates a pressure differential for measuring the flow of gas passing through the flow element.
- Oxygen analyzer 34 includes an oxygen analyzing element 35, which is essentially an airway adapter optical window and an O 2 transducer having phototransmitter and photodector, that is used to measure the amount of oxygen passing in front of the optical window.
- Flow sensor 33 and oxygen analyzing element 35 are preferably located proximate to the patient's airway. The outputs of the patient flow and oxygen analyzing systems are provided to a microprocessor 36 for calculating the patient's oxygen uptake.
- Cardiac output measurement device 30 includes means 38 for detecting a parameter indicative of the fractional arterial oxygen concentration, XaO 2 , of a patient.
- this parameter is any one of either SpO 2 , SaO 2 , PaO 2 , or CaO 2 .
- An example of a sensor that measures SpO 2 is a conventional pulse oximeter, and a sensor that measures SaO 2 , PaO 2 , or CaO 2 is a continuous indwelling catheter.
- a conversion to XaO 2 may be necessary. This can be done, for example, by microprocessor 36.
- the pulse oximeter includes a pulse oximeter sensor 39 in contact with the patient to measure the oxygen saturation SpO 2 of patient 37.
- cardiac output measurement device 30 includes an input/output interface 40 for communicating with the user.
- a display or other indicator may be provided that notifies the user when to induce that change in arterial oxygen concentration, as well as outputs the cardiac measurement result.
- a communication link 42 can also be provided for downloading or receiving information and commands to or from a remote location.
- One embodiment of the present invention contemplates that one or more of the patient flow measurement system, the oxygen analyzing system, and the fractional arterial oxygen concentration measuring system can be implemented in a separate, stand-alone, module with the output of each being provided to processor 36. This enables different types of patient flow, oxygen analyzing, and arterial oxygen concentration measuring systems to be used with a common cardiac output determination module.
- patient flow measuring system can be used to provide the required inputs to the cardiac output module.
- oxygen analyzing system can be used to provide the required inputs to the cardiac output module.
- arterial oxygen concentration measuring system can be integrated into a single housing 43, as shown, for example, in Fig. 12.
- the measuring elements of each system such as the flow element 33, the airway adapter and O 2 transducer 35, and the pulse oximeter sensor 39, provide inputs, e.g., electronic, optical, pneumatic, or otherwise, to one or more processing systems in housing 43.
- device 50 is a rebreathing system that captures the patient's expired gas in a collection reservoir 52.
- a valve 54 controls the flow of gas, so that when the cardiac output system is not actuated, the patient's airway communicates with ambient atmosphere or a conventional ventilator or pressure support system (not shown).
- valve 54 is controlled manually or via processor 36, to cause the patient's exhaled gas passed to reservoir 52 where it is collected. Because the gas collected in reservoir 52 has been exhaled by the patient, its oxygen concentration is significantly reduced.
- a device 56 for removing CO 2 is included in rebreathing system 50, so that the spontaneously breathing patient does not rebreathe significant amounts of CO 2 .
- device 56 is a CO 2 scrubber that removes CO 2 from the gas passing therethrough.
- CO 2 removal device 56 is optional, because their breathing pattern is controlled by the ventilator regardless of the CO 2 levels inhaled by the patient.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0014953-5A BR0014953A (en) | 1999-10-22 | 2000-10-19 | Method and apparatus for determining cardiac output |
AU19702/01A AU1970201A (en) | 1999-10-22 | 2000-10-19 | Method and apparatus for determining cardiac output |
CA002388652A CA2388652A1 (en) | 1999-10-22 | 2000-10-19 | Method and apparatus for determining cardiac output |
JP2001532657A JP2003531643A (en) | 1999-10-22 | 2000-10-19 | Cardiac output determination method and device |
EP00982709A EP1229826A4 (en) | 1999-10-22 | 2000-10-19 | Method and apparatus for determining cardiac output |
AU2005232306A AU2005232306A1 (en) | 1999-10-22 | 2005-11-11 | Method and apparatus for determining cardiac output |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16112099P | 1999-10-22 | 1999-10-22 | |
US60/161,120 | 1999-10-22 | ||
US09/691,595 US6413226B1 (en) | 1999-10-22 | 2000-10-18 | Method and apparatus for determining cardiac output |
US09/691,595 | 2000-10-18 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001030234A2 WO2001030234A2 (en) | 2001-05-03 |
WO2001030234A3 WO2001030234A3 (en) | 2001-12-06 |
WO2001030234A9 true WO2001030234A9 (en) | 2002-08-01 |
Family
ID=26857529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/041281 WO2001030234A2 (en) | 1999-10-22 | 2000-10-19 | Method and apparatus for determining cardiac output |
Country Status (7)
Country | Link |
---|---|
US (3) | US6413226B1 (en) |
EP (1) | EP1229826A4 (en) |
JP (1) | JP2003531643A (en) |
AU (1) | AU1970201A (en) |
BR (1) | BR0014953A (en) |
CA (1) | CA2388652A1 (en) |
WO (1) | WO2001030234A2 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7758503B2 (en) * | 1997-01-27 | 2010-07-20 | Lynn Lawrence A | Microprocessor system for the analysis of physiologic and financial datasets |
US8932227B2 (en) | 2000-07-28 | 2015-01-13 | Lawrence A. Lynn | System and method for CO2 and oximetry integration |
US9042952B2 (en) * | 1997-01-27 | 2015-05-26 | Lawrence A. Lynn | System and method for automatic detection of a plurality of SPO2 time series pattern types |
US20060161071A1 (en) | 1997-01-27 | 2006-07-20 | Lynn Lawrence A | Time series objectification system and method |
US20070191697A1 (en) | 2006-02-10 | 2007-08-16 | Lynn Lawrence A | System and method for SPO2 instability detection and quantification |
US6413226B1 (en) * | 1999-10-22 | 2002-07-02 | Respironics, Inc. | Method and apparatus for determining cardiac output |
US20060195041A1 (en) | 2002-05-17 | 2006-08-31 | Lynn Lawrence A | Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions |
US9053222B2 (en) | 2002-05-17 | 2015-06-09 | Lawrence A. Lynn | Patient safety processor |
US7135001B2 (en) * | 2001-03-20 | 2006-11-14 | Ric Investments, Llc | Rebreathing methods including oscillating, substantially equal rebreathing and nonrebreathing periods |
WO2006049485A1 (en) * | 2004-11-05 | 2006-05-11 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Method of and unit for determining the cardiac output of the human heart |
US7291688B2 (en) * | 2004-12-28 | 2007-11-06 | 3M Innovative Properties Company | Fluoroacrylate-mercaptofunctional copolymers |
GB2427691A (en) * | 2005-06-24 | 2007-01-03 | Micro Medical Ltd | Apparatus to detect patent foramen ovale |
WO2007065475A1 (en) * | 2005-12-06 | 2007-06-14 | Maquet Critical Care Ab | Method and apparatus for end expiratory lung volume estimation |
EP1968667A1 (en) * | 2005-12-29 | 2008-09-17 | Rikshospitalet- Radiumhospitalet HF | Method and apparatus for estimating a pao2 value for a patient subject to extracorporeal circulation |
US7668579B2 (en) | 2006-02-10 | 2010-02-23 | Lynn Lawrence A | System and method for the detection of physiologic response to stimulation |
WO2008010021A1 (en) * | 2006-07-12 | 2008-01-24 | Intertechnique | A respiratory gas supply circuit to feed crew members and passengers of an aircraft with oxygen |
US7925347B1 (en) | 2007-11-26 | 2011-04-12 | Pacesetter, Inc. | Assessment of cardiac output by implantable medical device |
EP2283443A1 (en) | 2008-05-07 | 2011-02-16 | Lynn, Lawrence A. | Medical failure pattern search engine |
JP4789974B2 (en) * | 2008-05-26 | 2011-10-12 | 順一 金子 | Near-infrared probe holder that can be placed on the surface of an in vivo organ or tissue |
GB2462304B (en) * | 2008-07-31 | 2010-12-01 | Laerdal Medical As | Device and method for detecting heart beats in a patient using the airway pressure |
DE102009013396B3 (en) * | 2009-03-16 | 2010-08-05 | Dräger Medical AG & Co. KG | Apparatus and method for controlling the oxygen dosage of a ventilator |
US9060722B2 (en) | 2009-04-22 | 2015-06-23 | Rodrigo E. Teixeira | Apparatus for processing physiological sensor data using a physiological model and method of operation therefor |
US9173574B2 (en) | 2009-04-22 | 2015-11-03 | Rodrigo E. Teixeira | Mechanical health monitor apparatus and method of operation therefor |
US9451886B2 (en) | 2009-04-22 | 2016-09-27 | Rodrigo E. Teixeira | Probabilistic parameter estimation using fused data apparatus and method of use thereof |
US9375171B2 (en) * | 2009-04-22 | 2016-06-28 | Rodrigo E. Teixeira | Probabilistic biomedical parameter estimation apparatus and method of operation therefor |
US9049994B2 (en) | 2011-09-21 | 2015-06-09 | Siemens Medical Solutions Usa, Inc. | System for cardiac arrhythmia detection and characterization |
US9332917B2 (en) | 2012-02-22 | 2016-05-10 | Siemens Medical Solutions Usa, Inc. | System for non-invasive cardiac output determination |
US9439577B2 (en) | 2012-03-27 | 2016-09-13 | The University Of Vermont And State Agricultural College | Non-invasive methods for determining cardiac output |
US9241646B2 (en) | 2012-09-11 | 2016-01-26 | Covidien Lp | System and method for determining stroke volume of a patient |
WO2015013450A1 (en) * | 2013-07-25 | 2015-01-29 | Mayo Foundation For Medical Education And Research | Computer-based analysis of oscillatory ventilation |
US9180260B2 (en) | 2013-08-30 | 2015-11-10 | Covidien Lp | Systems and methods for monitoring an injection procedure |
US10405757B2 (en) | 2014-02-25 | 2019-09-10 | Icu Medical, Inc. | Patient monitoring system with gatekeeper signal |
US20160058346A1 (en) * | 2014-09-02 | 2016-03-03 | General Electric Company | Determination of arterial co2 partial pressure |
DK3243152T3 (en) * | 2015-01-09 | 2019-06-11 | Mermaid Care As | Systems and methods for identifying the need for cardiac output measurement |
US10007238B1 (en) * | 2015-01-22 | 2018-06-26 | John C. Taube | Oxygen mixing and delivery |
CN107735135B (en) | 2015-04-02 | 2020-06-26 | 希尔-罗姆服务私人有限公司 | Manifold for a respiratory device |
CN105311721B (en) * | 2015-09-10 | 2019-04-02 | 广州弘凯物联网服务有限公司 | A kind of oxygen therapy method for quality control and its system |
EP3364860A4 (en) | 2015-10-19 | 2019-09-18 | ICU Medical, Inc. | Hemodynamic monitoring system with detachable display unit |
US11779720B2 (en) | 2019-11-04 | 2023-10-10 | Vapotherm, Inc. | Methods, devices, and systems for improved oxygenation patient monitoring, mixing, and delivery |
US11612706B2 (en) | 2019-11-25 | 2023-03-28 | John C. Taube | Methods, systems, and devices for controlling mechanical ventilation |
US20240050676A1 (en) * | 2020-12-16 | 2024-02-15 | Koninklijke Philips N.V. | Visualizing and simulating changes in oxygenation |
EP4014861A1 (en) * | 2020-12-16 | 2022-06-22 | Koninklijke Philips N.V. | Graphical representation of oxygenation |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896792A (en) * | 1974-05-15 | 1975-07-29 | Us Navy | Real-time cyclic pulmonary function test system |
US4127121A (en) * | 1976-09-17 | 1978-11-28 | University Of Utah | Oxygen and anesthesia delivery and monitoring device |
US4169465A (en) * | 1977-05-04 | 1979-10-02 | James A. Walls | Method and apparatus for obtaining non-invasive cardio-pulmonary measurements |
US4966141A (en) * | 1988-06-13 | 1990-10-30 | Bacaner Marvin B | Endotracheal tube and mass spectrometer |
US4949724A (en) * | 1988-12-23 | 1990-08-21 | Mahutte Cornelis K | Method and apparatus for continuous measurement of cardiac output |
SE465497B (en) * | 1989-11-24 | 1991-09-23 | Minco Ab | DEVICE FOR STUDYING A PERSON'S LUNG FUNCTION |
DE59207599D1 (en) | 1991-03-25 | 1997-01-16 | Andreas Prof Dr Med Hoeft | Device and method for determining cardiac output |
US5505209A (en) | 1994-07-07 | 1996-04-09 | Reining International, Ltd. | Impedance cardiograph apparatus and method |
US5800361A (en) | 1995-02-06 | 1998-09-01 | Ntc Technology Inc. | Non-invasive estimation of arterial blood gases |
US6132120A (en) * | 1995-03-29 | 2000-10-17 | Brother Kogyo Kabushiki Kaisha | Tape-shaped label printing device |
US5634461A (en) * | 1995-06-07 | 1997-06-03 | Alliance Pharmaceutical Corp. | System for measuring blood oxygen levels |
US6390977B1 (en) * | 1995-06-07 | 2002-05-21 | Alliance Pharmaceutical Corp. | System and methods for measuring oxygenation parameters |
GB9600209D0 (en) | 1996-01-05 | 1996-03-06 | Monitoring Tech Ltd | Improved method and apparatus for the measurement of cardiac output |
US5836300A (en) * | 1996-03-11 | 1998-11-17 | Mault; James R. | Metabolic gas exchange and noninvasive cardiac output monitor |
US6135107A (en) * | 1996-03-11 | 2000-10-24 | Mault; James R. | Metabolic gas exchange and noninvasive cardiac output monitor |
EP0936888A1 (en) | 1996-09-28 | 1999-08-25 | Technische Universität Dresden | Device to determine effective pulmonary blood flow |
US5971934A (en) | 1996-10-04 | 1999-10-26 | Trustees Of The University Of Pennsylvania | Noninvasive method and apparatus for determining cardiac output |
AUPO322396A0 (en) * | 1996-10-25 | 1996-11-21 | Robinson, Gavin J.B. Dr | A method of measuring cardiac output by pulmonary exchange of oxygen and an inert gas with the blood utilising a divided airway |
US6306098B1 (en) | 1996-12-19 | 2001-10-23 | Novametrix Medical Systems Inc. | Apparatus and method for non-invasively measuring cardiac output |
US5788647A (en) * | 1997-01-24 | 1998-08-04 | Eggers; Philip E. | Method, system and apparatus for evaluating hemodynamic parameters |
US6309360B1 (en) * | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
US6099481A (en) | 1997-11-03 | 2000-08-08 | Ntc Technology, Inc. | Respiratory profile parameter determination method and apparatus |
US6572561B2 (en) * | 1998-01-16 | 2003-06-03 | Healthetech, Inc. | Respiratory calorimeter |
US6106460A (en) * | 1998-03-26 | 2000-08-22 | Scimed Life Systems, Inc. | Interface for controlling the display of images of diagnostic or therapeutic instruments in interior body regions and related data |
US6186956B1 (en) | 1998-05-28 | 2001-02-13 | University Of South Carolina | Method and system for continuously monitoring cardiac output |
US6200271B1 (en) | 1998-09-09 | 2001-03-13 | Ntc Technology Inc. | Bi-directional partial re-breathing method |
US6042550A (en) | 1998-09-09 | 2000-03-28 | Ntc Technology, Inc. | Methods of non-invasively estimating intrapulmonary shunt fraction and measuring cardiac output |
US6238351B1 (en) | 1998-09-09 | 2001-05-29 | Ntc Technology Inc. | Method for compensating for non-metabolic changes in respiratory or blood gas profile parameters |
US6217524B1 (en) | 1998-09-09 | 2001-04-17 | Ntc Technology Inc. | Method of continuously, non-invasively monitoring pulmonary capillary blood flow and cardiac output |
US6098622A (en) | 1998-10-15 | 2000-08-08 | Ntc Technology Inc. | Airway valve to facilitate re-breathing, method of operation, and ventilator circuit so equipped |
US6186955B1 (en) | 1998-11-16 | 2001-02-13 | Gail D. Baura | Noninvasive continuous cardiac output monitor |
US6406435B1 (en) | 1998-11-17 | 2002-06-18 | James R. Mault | Method and apparatus for the non-invasive determination of cardiac output |
US6162180A (en) | 1998-12-28 | 2000-12-19 | Medtronic, Inc. | Non-invasive cardiac monitoring system and method with communications interface |
JP2002535024A (en) * | 1999-01-21 | 2002-10-22 | メタセンサーズ,インコーポレイティド | Non-invasive monitoring of cardiac output and lung function using respiratory gas analysis techniques and physiological models |
JP2003527881A (en) * | 1999-05-10 | 2003-09-24 | ジェームズ アール モールト | Airway-based cardiac output monitor and method of using the same |
US6228351B1 (en) | 1999-05-27 | 2001-05-08 | Daniel E. Viders | Medicated lip balm |
US6210342B1 (en) | 1999-09-08 | 2001-04-03 | Ntc Technology, Inc. | Bi-directional partial re-breathing method |
US6413226B1 (en) * | 1999-10-22 | 2002-07-02 | Respironics, Inc. | Method and apparatus for determining cardiac output |
-
2000
- 2000-10-18 US US09/691,595 patent/US6413226B1/en not_active Expired - Fee Related
- 2000-10-19 JP JP2001532657A patent/JP2003531643A/en active Pending
- 2000-10-19 WO PCT/US2000/041281 patent/WO2001030234A2/en active Application Filing
- 2000-10-19 BR BR0014953-5A patent/BR0014953A/en not_active Application Discontinuation
- 2000-10-19 AU AU19702/01A patent/AU1970201A/en not_active Abandoned
- 2000-10-19 CA CA002388652A patent/CA2388652A1/en not_active Abandoned
- 2000-10-19 EP EP00982709A patent/EP1229826A4/en active Pending
-
2002
- 2002-06-14 US US10/172,271 patent/US6699203B2/en not_active Expired - Fee Related
-
2004
- 2004-01-23 US US10/763,971 patent/US7367954B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2001030234A3 (en) | 2001-12-06 |
US20030013980A1 (en) | 2003-01-16 |
WO2001030234A2 (en) | 2001-05-03 |
JP2003531643A (en) | 2003-10-28 |
US20040171950A1 (en) | 2004-09-02 |
AU1970201A (en) | 2001-05-08 |
US6413226B1 (en) | 2002-07-02 |
US7367954B2 (en) | 2008-05-06 |
EP1229826A2 (en) | 2002-08-14 |
EP1229826A4 (en) | 2008-04-23 |
BR0014953A (en) | 2002-06-18 |
US6699203B2 (en) | 2004-03-02 |
CA2388652A1 (en) | 2001-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6413226B1 (en) | Method and apparatus for determining cardiac output | |
US6258038B1 (en) | Methods of non-invasively estimating intrapulmonary shunt fraction and measuring cardiac output | |
EP0999783B1 (en) | Apparatus and method for non-invasively measuring cardiac output | |
US6616615B2 (en) | Respiratory calorimeter | |
Jaffe | Partial CO2 rebreathing cardiac output–operating principles of the NICO™ system | |
US6217524B1 (en) | Method of continuously, non-invasively monitoring pulmonary capillary blood flow and cardiac output | |
US7025731B2 (en) | Methods for accurately, substantially noninvasively determining pulmonary capillary blood flow, cardiac output, and mixed venous carbon dioxide content | |
US7699788B2 (en) | Noninvasive effective lung volume estimation | |
US6200271B1 (en) | Bi-directional partial re-breathing method | |
US6210342B1 (en) | Bi-directional partial re-breathing method | |
US7070569B2 (en) | Non-invasive determination of conditions in the circulatory system of a subject | |
EP0449971A4 (en) | Methods and apparatus for cardiac output measurement | |
US20060004297A1 (en) | Lung model-based cardiopulmonary performance determination | |
US20030167016A1 (en) | Airway-based cardiac output monitor and methods for using same | |
US6102868A (en) | Method and system for measuring the cardiac output of a living being | |
AU2005232306A1 (en) | Method and apparatus for determining cardiac output |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19702/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2388652 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 532657 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000982709 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWP | Wipo information: published in national office |
Ref document number: 2000982709 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |